Previous close | 0.6000 |
Open | 0.6000 |
Bid | 0.0000 |
Ask | 0.8000 |
Strike | 52.50 |
Expiry date | 2024-06-21 |
Day's range | 0.6000 - 0.6000 |
Contract range | N/A |
Volume | |
Open interest | 94 |
As an investor its worth striving to ensure your overall portfolio beats the market average. But its virtually certain...
SOMERSET, N.J., May 29, 2024--Catalent, Inc. ("Catalent," NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, today announced that, at its Special Meeting of Stockholders (the "Special Meeting") held earlier today, its stockholders voted to approve the pending transaction under which Novo Holdings A/S ("Novo Holdings") will acquire all outstanding shares of Catalent for $63.50 per share in cash (the "Merger").
Catalent's (CTLT) new tie-up to support the development and commercial manufacturing of safe, high-quality AAV gene therapies to provide life-saving treatments to cancer patients.